These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 33929896)
1. Fibroblast growth factor 23 (FGF23) induces ventricular arrhythmias and prolongs QTc interval in mice in an FGF receptor 4-dependent manner. Graves JM; Vallejo JA; Hamill CS; Wang D; Ahuja R; Patel S; Faul C; Wacker MJ Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2283-H2294. PubMed ID: 33929896 [TBL] [Abstract][Full Text] [Related]
2. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. Grabner A; Schramm K; Silswal N; Hendrix M; Yanucil C; Czaya B; Singh S; Wolf M; Hermann S; Stypmann J; Di Marco GS; Brand M; Wacker MJ; Faul C Sci Rep; 2017 May; 7(1):1993. PubMed ID: 28512310 [TBL] [Abstract][Full Text] [Related]
3. Hypericin Alleviates Chronic Kidney Disease-induced Left Ventricular Hypertrophy by Regulation of FGF23-FGFR4 Signaling Pathway. Liu M; Cheng L; Ye Q; Liu H; Shu C; Gao H; Liu X; Zhang X; Chen G J Cardiovasc Pharmacol; 2024 Jun; 83(6):588-601. PubMed ID: 38547517 [TBL] [Abstract][Full Text] [Related]
4. FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice. Han X; Cai C; Xiao Z; Quarles LD J Mol Cell Cardiol; 2020 Jan; 138():66-74. PubMed ID: 31758962 [TBL] [Abstract][Full Text] [Related]
5. Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats. Leifheit-Nestler M; Grabner A; Hermann L; Richter B; Schmitz K; Fischer DC; Yanucil C; Faul C; Haffner D Nephrol Dial Transplant; 2017 Sep; 32(9):1493-1503. PubMed ID: 28339837 [TBL] [Abstract][Full Text] [Related]
6. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Grabner A; Amaral AP; Schramm K; Singh S; Sloan A; Yanucil C; Li J; Shehadeh LA; Hare JM; David V; Martin A; Fornoni A; Di Marco GS; Kentrup D; Reuter S; Mayer AB; Pavenstädt H; Stypmann J; Kuhn C; Hille S; Frey N; Leifheit-Nestler M; Richter B; Haffner D; Abraham R; Bange J; Sperl B; Ullrich A; Brand M; Wolf M; Faul C Cell Metab; 2015 Dec; 22(6):1020-32. PubMed ID: 26437603 [TBL] [Abstract][Full Text] [Related]
7. The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23. Navarro-García JA; Salguero-Bodes R; González-Lafuente L; Martín-Nunes L; Rodríguez-Sánchez E; Bada-Bosch T; Hernández E; Mérida-Herrero E; Praga M; Solís J; Arribas F; Bueno H; Kuro-O M; Fernández-Velasco M; Ruilope LM; Delgado C; Ruiz-Hurtado G BMC Med; 2022 Jan; 20(1):14. PubMed ID: 35042527 [TBL] [Abstract][Full Text] [Related]
8. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731 [TBL] [Abstract][Full Text] [Related]
9. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Touchberry CD; Green TM; Tchikrizov V; Mannix JE; Mao TF; Carney BW; Girgis M; Vincent RJ; Wetmore LA; Dawn B; Bonewald LF; Stubbs JR; Wacker MJ Am J Physiol Endocrinol Metab; 2013 Apr; 304(8):E863-73. PubMed ID: 23443925 [TBL] [Abstract][Full Text] [Related]
10. QTc Interval Prolongation Is Independently Associated with FGF23 and Predicts Mortality in Predialysis Chronic Kidney Disease. Sikaneta T; Ho N; Bellasi A; Mahdavi S; Taskapan H; Svendrovski A; Makanjee B; Roberts J; Wu G; Nathoo B; Tam P Cardiorenal Med; 2024; 14(1):45-57. PubMed ID: 37963445 [TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Singh S; Grabner A; Yanucil C; Schramm K; Czaya B; Krick S; Czaja MJ; Bartz R; Abraham R; Di Marco GS; Brand M; Wolf M; Faul C Kidney Int; 2016 Nov; 90(5):985-996. PubMed ID: 27457912 [TBL] [Abstract][Full Text] [Related]
12. FGFR4 does not contribute to progression of chronic kidney disease. Taylor A; Yanucil C; Musgrove J; Shi M; Ide S; Souma T; Faul C; Wolf M; Grabner A Sci Rep; 2019 Oct; 9(1):14023. PubMed ID: 31575945 [TBL] [Abstract][Full Text] [Related]
13. C-terminal fragment of fibroblast growth factor 23 improves heart function in murine models of high intact fibroblast growth factor 23. Hu MC; Reneau JA; Shi M; Takahashi M; Chen G; Mohammadi M; Moe OW Am J Physiol Renal Physiol; 2024 Apr; 326(4):F584-F599. PubMed ID: 38299214 [TBL] [Abstract][Full Text] [Related]
14. Cardioprotective Effects of Paricalcitol Alone and in Combination With FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies. Czaya B; Seeherunvong W; Singh S; Yanucil C; Ruiz P; Quiroz Y; Grabner A; Katsoufis C; Swaminathan S; Abitbol C; Rodriguez-Iturbe B; Faul C; Freundlich M Am J Hypertens; 2019 Jan; 32(1):34-44. PubMed ID: 30329020 [TBL] [Abstract][Full Text] [Related]
15. Exploring the implications of blocking renin-angiotensin-aldosterone system and fibroblast growth factor 23 in early left ventricular hypertrophy without chronic kidney disease. Watanabe K; Fujii H; Okamoto K; Kono K; Goto S; Nishi S Front Endocrinol (Lausanne); 2023; 14():1276664. PubMed ID: 38174329 [TBL] [Abstract][Full Text] [Related]